

Health Technology Review

# Opioid Analgesics to Treat Chronic Noncancer Pain Among Patients Prescribed Opioid Agonist Therapy or With Opioid Use Disorder

PROSPERO Registration Number: CRD42023475381

## Table of Contents

List of Tables .....	3
List of Figures .....	3
Abbreviations.....	4
Introduction and Rationale .....	6
Project Scope and Protocol Development.....	8
Objectives.....	8
Deliverables .....	8
Policy Questions .....	9
Research Questions .....	9
Clinical Review Methods .....	10
Opportunities for Stakeholder Feedback.....	14
Areas for Potential Amendments.....	14
References.....	15
Appendix 1: Literature Search Strategy .....	18
Appendix 2: Content and Methodological Experts .....	49

## List of Tables

Table 1: Selection Criteria..... 8

## List of Figures

Figure 1: Summary of Evidence Reviews and Source of Studies..... 9

## Abbreviations

<b>AMED</b>	Allied and Complementary Medicine Database
<b>CI</b>	confidence interval
<b>OAT</b>	opioid agonist therapy
<b>OR</b>	odds ratio
<b>OUD</b>	opioid use disorder
<b>RCT</b>	randomized controlled trial

## Introduction and Rationale

Opioid use disorder (OUD) is a chronic and relapsing pattern of opioid use associated with significant impairment. It may occur in the context of prescription opioid use (i.e., for analgesia), street opioid use, or the combination of both.<sup>1,2</sup> OUD is a growing public health concern across North America and disproportionately impacts some social groups.<sup>3</sup>

In Canada, the prevalence of OUD varies across jurisdictions, with the estimated prevalence in British Columbia (1.92%) being 2 times the nationwide prevalence.<sup>3,4</sup> Likewise, rates of opioid-related harms vary nationally, with fatalities and hospitalization rates being highest in Canada's western jurisdictions.<sup>5</sup> OUD and opioid-related harms remain serious issues across the country, with opioid overdoses among the leading causes of death in adults.<sup>3</sup> The national rate of apparent opioid toxicity deaths in 2022 was estimated to be approximately 19 per 100,000 population<sup>5</sup> and harms have accelerated during the COVID-19 pandemic; for example, in Ontario, opioid-related life-threatening emergency department visits increased by 57% and opioid-related deaths increased by 60%.<sup>6,7</sup>

### Chronic Noncancer Pain and OUD Comorbidity

Chronic pain, defined as pain lasting 3 months or longer, is also a major clinical and public health issue, with about 1 in 5 people in Canada (nearly 8 million people) living with chronic pain.<sup>8</sup> People with OUD are more likely to live with chronic pain, as indicated by a systematic review that reported rates as high as 45%.<sup>9</sup> Upwards of 8% of individuals with chronic pain are estimated to have a history of OUD.<sup>10</sup>

There is a complex interplay between these 2 conditions. Chronic pain may precede or follow a diagnosis of OUD<sup>11,12</sup> as prolonged use of opioid analgesics for the management of chronic pain can increase the risk of developing OUD, while people with a history of OUD who also have chronic pain may use opioid analgesics that exacerbate their addiction.<sup>13</sup> People with chronic pain often take opioid analgesics for pain management, and with regular use will develop physical dependence to these medications. In 2018, 12.7% of people living in Canada (approximately 3.7 million) aged  $\geq 15$  years reported using opioids for pain relief over the past 12 months; of these, 9.7% (approximately 351,000) engaged in problematic use (defined in the study as taking opioids in greater amounts or more often than directed, intentionally using them for the experience or to get high, using opioids meant for pain management for reasons other than pain relief, and tampering with a product before taking it).<sup>14</sup>

The co-occurrence of chronic pain and OUD is associated with a 55% increased likelihood of overdose relative to those with OUD and without chronic pain (odds ratio [OR] = 1.55, 95% CI, 1.16 to 2.08).<sup>15</sup> Furthermore, increased severity of chronic pain in individuals with OUD is associated with worse health-related quality of life.<sup>15</sup> While chronic pain is already routinely linked to poor psychosocial functioning, reduced quality of life, and poor self-rated health, the impacts of chronic pain are likely worse in individuals with OUD.<sup>17</sup>

The majority of people with OUD also have at least 1 coexisting psychiatric disorder.<sup>11,16-18</sup> This is of heightened concern among individuals with co-occurring OUD and chronic pain: a meta-analysis showed that

the likelihood of psychiatric comorbidity in individuals with OUD was more than 2 times as high in those with co-occurring chronic pain than in those without chronic pain (OR = 2.18; 95% confidence interval [CI], 1.6 to 2.9).<sup>19</sup> Other studies have similarly suggested that the prevalence of mental health concerns is significantly higher in people with OUD that have chronic pain (67% to 78%) than in those without chronic pain (51% to 58%).<sup>13,20</sup>

Given the high rates and complexities of this comorbidity, effective guidance for the management of chronic pain is critical for improving the care of people with OUD.<sup>11</sup>

### Available Treatment for Co-Occurring OUD and Chronic Pain and Challenges

Managing chronic pain in individuals with OUD presents unique challenges.<sup>11</sup> In many jurisdictions, opioid agonist therapy (OAT), commonly using methadone, buprenorphine, and/or slow-release oral morphine,<sup>2,10,21,22</sup> is considered a first-line therapy for OUD. However, OAT alone may be insufficient to effectively manage chronic pain in people with OUD;<sup>10</sup> for example, though buprenorphine formulations are widely used for analgesic purposes, buprenorphine has been found to provide limited analgesic effect in individuals with co-occurring OUD and chronic pain.<sup>23</sup>

Clinical practice guidelines for the management of OUD<sup>2,24-28</sup> frequently include recommendations for treating chronic pain in patients with OUD, though the evidence supporting these guidance statements for chronic pain management is limited. Most guidelines recommend that patients with co-occurring OUD and chronic pain should be supported in exploring alternative pain treatments, such as nonopioid pharmacotherapies (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs], anticonvulsants, and tricyclic antidepressants)<sup>2,24,26</sup> and nonpharmacological therapies (e.g., cognitive behavioural therapy),<sup>2,25,26</sup> that are accessible and culturally appropriate.

Evidence supporting the use of cognitive behavioural therapy<sup>29,30</sup> and mindfulness-oriented recovery<sup>31</sup> for treating chronic pain in patients with OUD is growing, but further studies are needed to establish their effectiveness in this context. Likewise, many medical professionals prescribe nonopioid medications for chronic pain; however, despite some positive findings, the analgesic effects of nonopioid medications for people with OUD are modest at best.<sup>32</sup>

These therapeutic limitations highlight the need to consider appropriate analgesic options in this comorbid context. One algorithm for managing chronic pain in patients with substance use disorders recommends using opioid analgesics when patients do not adequately benefit from other treatments, namely agonist therapy, nonpharmacological pain treatment, and psychiatric and/or sleep disturbance treatments.<sup>33</sup> Of note, with regards to efficacy, a meta-analysis found that opioid use among patients with chronic noncancer pain was associated with statistically significant, but clinically modest, improvements in pain, sleep, and physical functioning; however, patients with comorbid OUD were typically excluded from these trials.<sup>34</sup>

Not all patients are the same, nor will they experience treatments the same. Rather, decision-making around therapeutic trials is informed by patient values and preferences, costs, accessibility, and other concerns.<sup>35</sup> While the risks and adverse effects related to opioids are significant, some individuals may still prefer them if they feel their pain relief benefits outweigh the side effects and concerns.<sup>36</sup>

Opioid analgesics are 1 option for chronic pain in patients with OUD. As it stands, however, guidance on the use of opioid analgesics to manage pain in this population is limited.<sup>19</sup> As concerns around poorly treated pain, opioid-related harms, health service utilization, accessibility, and costs grow, developing evidence-informed strategies for managing chronic pain in individuals with OUD and/or a history of OAT is critical.<sup>11</sup> Making relevant evidence readily available to patients, clinicians, health administrators, and policy-makers through evidence synthesis can support evidence-informed decision-making in this complex area. Accordingly, this project aims to summarize evidence on the efficacy, effectiveness, and safety of opioid analgesics in managing chronic pain in patients with OUD, a history of OUD, receiving OAT, and/or a history of receiving OAT.

## Project Scope and Protocol Development

The methodology employed for this review follows the guidelines outlined in the Cochrane Handbook.<sup>37</sup> Reporting of the protocol adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Protocols (PRISMA-P).<sup>38</sup> Following the scoping and refinement process, the group finalized the research and policy questions and selection criteria with jurisdictional input.

The protocol was developed by the Subject Matter Health Research Lab based out of Humber River Health, in collaboration with CADTH and content and methodological experts (refer to [Appendix 2](#)). The protocol will be posted on the CADTH website for stakeholder feedback. This protocol has been submitted for registration in PROSPERO (international prospective register of systematic review). The evidence syntheses will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 reporting guidelines.<sup>39</sup>

## Objectives

The main objective of this evidence synthesis is to explore the safety, efficacy, and effectiveness of opioid analgesics for the management of chronic pain for people with OUD, with a history of OUD, who are currently receiving OAT, and/or were previously receiving OAT.

## Deliverables

The following deliverables are planned:

- a Protocol
- a Science Report
- a Summary and visual tool to aid knowledge dissemination.

## Policy Questions

1. How can opioid analgesics be used safely and effectively in patients with chronic pain who are currently, or were previously, receiving OAT?
2. How can opioid analgesics be used safely and effectively in patients with chronic pain who are not receiving OAT and have an OUD or a history of OUD?
3. Are patients with chronic pain who are currently, or were previously, receiving OAT at a higher risk of overdose or relapse? Is there a duration of sustained remission from OUD where the patient is at minimal risk of relapse?

## Research Questions

The project will address the following research questions. Details on the specific interventions and outcomes are included in [Table 1](#).

1. In people with chronic pain who have OUD or a history of OUD, what is the effect of solitary use of opioid analgesics or concurrent use of opioid analgesics with OAT versus any comparison or no comparison on any effectiveness outcomes including pain intensity, health-related quality of life, physical functioning, emotional functioning (anxiety, depression), and global rating of improvement?
2. In people with chronic pain who have OUD or a history of OUD, what is the effect of solitary use of opioid analgesics or concurrent use of opioid analgesics with OAT versus any comparison or no comparison on any safety outcomes, including relapse, increased substance use, extramedical use, opioid-related toxicity, hospitalization, and death?

**Table 1: Selection Criteria**

Criteria	Description
<b>Populations</b>	Adults with CNCP who have a diagnosis of OUD or a history of OUD
<b>Intervention</b>	Solitary use of opioid analgesics or concurrent use of opioid analgesics and OAT (i.e., buprenorphine with or without naloxone, methadone, and slow-release morphine)
<b>Comparators</b>	Any comparator, including no treatment
<b>Outcomes</b>	Any 1 of, or combination of, the following: <ul style="list-style-type: none"> <li>• Efficacy and effectiveness: pain intensity, HRQoL, physical functioning, emotional functioning (e.g., anxiety and depression), and global rating of improvement<sup>40</sup></li> <li>• Safety: relapse, misuse, abuse, diversion, overdose, hospitalization, death</li> </ul>
<b>Study designs</b>	Randomized controlled trial, clinical practice guidelines, systematic reviews, open-label treatment studies, observational (prospective or retrospective) studies, including cohort, case-control, and cross-sectional studies. The primary research studies informing clinical practice guidelines will also be used.

CNCP = chronic noncancer pain; HRQoL = health-related quality of life; OAT = opioid agonist therapy; OUD = opioid use disorder.



## Clinical Review Methods

### Literature Search Methods


This evidence synthesis will focus on 2 kinds of outcomes (i.e., efficacy or effectiveness, and safety) informed by 2 bodies of evidence, namely randomized controlled trials (RCTs) and real-world evidence in the form of well-designed observational studies. As such, this synthesis will be informed by 4 subreviews focusing on: efficacy using RCT data, safety using RCT data, effectiveness using observational study data, and safety using observational study data (refer to [Figure 1](#)).

RCTs provide more robust evidence for establishing cause and effect relationships between interventions and outcomes due to their rigorous design and aspirations to control for confounding factors. However, observational studies are valuable for studying real-world scenarios and assessing associations between variables that might be difficult or unethical to study through RCTs.<sup>41,42</sup>

Observational studies may provide better representativeness for the target questions; RCTs often exclude patients with prior or current OUD, which can limit their applicability to real-world situations. Furthermore, observational studies are more appropriate for studying long-term and infrequent or rare harms. RCTs are typically small in scale and follow participants for fewer than 6 months, making it difficult to capture and assess long-term effects and rare adverse events.<sup>43</sup>

Both types of studies contribute to the body of evidence in health research, and researchers, clinicians, and policy-makers often use a combination of both to draw more comprehensive conclusions and inform practice and policy.<sup>41,42</sup>

**Figure 1: Summary of Evidence Reviews and Source of Studies**



vs. = versus.

### **RCT Data — Efficacy and Safety**

Efficacy and safety of opioid analgesics for treating chronic pain in individuals with OUD or a history of OUD, or who are receiving OAT and/or were previously treated with OAT will be assessed using data from RCTs. The 2017 Canadian Opioid Prescribing Guideline<sup>44</sup> was endorsed by a systematic review and meta-analysis with PROSPERO identifier CRD42012003023 that explored the efficacy and safety of opioid analgesics for treating chronic pain.<sup>34</sup> The authors included RCTs that explored the efficacy and safety of opioid analgesics versus any nonopioid analgesics. The review reported several outcomes, including pain relief, quality of life subscores, quality of sleep, and adverse events caused by opioids.

In preparation for the 2023 update, the evidence synthesis team for the guideline has updated a search for RCTs on MEDLINE, EMBASE, PsycINFO, CINAHL, the Allied and Complementary Medicine Database (AMED), and Cochrane Central from inception to July 2023. They have also reviewed the reference list of all included studies and relevant reviews.<sup>45</sup> For this project, the included studies from this update will be screened against the inclusion criteria for this project to specifically identify RCTs that have examined efficacy and safety within the context of OUD and OAT.

### **Real-World Evidence From Observational Studies — Effectiveness**

For the effectiveness research question, we registered and followed a novel protocol to capture real-world evidence in PROSPERO (Identifier: CRD42023475381). For this body of evidence, an experienced medical librarian will design the search strategy by using controlled vocabulary and keywords representing the concepts “opioid,” “chronic pain,” and “opioid use disorder” (refer to [Appendix 1](#)). The evidence synthesis team will adapt the search strategy and conduct systematic literature searches in MEDLINE, EMBASE, PsycINFO, CINAHL, and AMED from inception to September 2023 without language restrictions. The evidence synthesis team will use the CADTH search filters for study designs to limit our search to observational studies, systematic reviews with or without meta-analyses, and guidelines to identify real-world evidence for the effectiveness of opioid analgesics in treating patients with chronic pain who have OUD or a history of OUD, and/or are receiving OAT or have previously received OAT. After getting feedback from stakeholders, the search strategy will be reviewed following the Peer Review of Electronic Search (PRESS) guidance.<sup>46</sup>

### **Real-World Evidence From Observational Studies — Safety**

The study team responsible for updating the 2017 Canadian Opioid Prescribing Guideline has conducted 2 systematic reviews and meta-analyses exploring predictors of fatal and nonfatal overdose and OUD (PROSPERO registration numbers CRD42017050972 and CRD42019119184) following prescription of opioid analgesics for chronic pain. Those reviews used observational studies to evaluate the risk factors associated with opioid overdose, opioid addiction, and death from opioid use, as well as OUD following the prescription of opioid analgesics for treating chronic pain. For both reviews, a health sciences librarian developed a search strategy and systematically searched MEDLINE, EMBASE, CINAHL, PsycINFO, and AMED from inception to July 2023. The evidence synthesis team will review the bibliographic references of the included studies and related reviews for additional potentially eligible citations. The evidence synthesis team will screen eligible studies from these reviews and include articles that enrolled patients with chronic pain

who had OUD or those with a history of OUD and/or receiving OAT or previously treated with OAT, or explored these factors for their association with the relevant outcomes.

### **Updates**

For all data sources, including RCTs and observational studies, alerts will occur until the draft report is in the publishing phase; however, the primary study results will be incorporated into the results section until the start of the stakeholder feedback and external review phase. Any relevant studies identified after this point will be described and referenced in the Summary of Results section.

## **Selection and Eligibility Criteria**

### **Study Selection**

For records obtained from the Canadian opioid guideline team, 2 reviewers will independently assess eligibility based on the predetermined selection criteria using the full text of the studies (refer to [Table 1](#)). This will be done using the web-based systematic review software Covidence, which was developed by Veritas Health Innovation in Melbourne, Australia, as 3 separate reviews to facilitate appropriate tracking of records and selections.

For the novel search for observational effectiveness data, pairs of reviewers will use Covidence and a standardized form to independently screen the titles and abstracts identified through our literature searches for relevance to the clinical research question. Before the formal screening process, we will perform multiple rounds of screening to achieve agreement. For each round, 50 titles and abstracts and 10 full texts will be used for pilot screening. Pairs from the same set of reviewers will independently assess the full texts of all potentially eligible articles based on the predetermined selection criteria (refer to [Table 1](#)).

All conflicts will be resolved through discussion to reach consensus, and if needed, a senior reviewer will be involved. The study selection process will be presented in a PRISMA flow chart.

### **Inclusion and Exclusion Criteria**

The evidence synthesis team will include RCTs of any design and observational studies, inclusive of both comparative and 1-arm observational studies that enrol at least 20 participants in their cohort. The team will include studies that enrolled adults with chronic pain (defined as pain lasting  $\geq 3$  months) who have OUD, have a history of OUD, are currently receiving OAT, and/or were previously receiving OAT and will compare opioid analgesics versus any comparators (including no treatment). For studies that enrolled a mixed population, the evidence synthesis team will include those that reported results for participants of interest separately or for at least 85% of the enrolled patients according to the eligibility criteria of our systematic review (refer to [Table 1](#)).

Case reports, case series, and conference abstracts will not be considered eligible. We will also exclude studies that enrolled patients presenting with acute pain (including acute postoperative pain), those with chronic pain related to cancer, those with end-of-life pain, and those receiving palliative or hospice care.

## Data Extraction and Critical Appraisal

A data extraction form in Excel will be developed and the extraction criteria will be pilot tested. All reviewers will extract data from a subset of studies, and the evidence synthesis team will compare and review their data against the extractions of a subject matter expert. After reaching a consensus on the data extraction criteria, pairs of reviewers will independently extract data. The aim is to collect 5 groups of data: study characteristics (i.e., author, year, country, source of funding, and setting), study methods (i.e., study design, number of arms, primary objective, and research question), participant information (i.e., inclusion and exclusion criteria, age, sex, race and ethnicity, education level, underlying cause of chronic pain, study definition of OUD, information regarding current use of OAT, previous treatment with OAT, diagnosis of OUD, history of OUD, and coexisting psychiatric comorbidity), interventions and comparison (i.e., dose, duration and timing, formulation, route of administration, and comedication information), and outcomes (i.e., tools, scale of measurement, range, direction of outcome, and longest length of follow-up). The primary efficacy and effectiveness outcomes of interest are pain intensity, health-related quality of life, physical functioning, emotional functioning, and global rating of improvement. The primary safety outcomes are relapse, misuse, abuse, diversion, overdose, hospitalization, and death. All conflicts regarding data extraction will be resolved through discussion and, if needed, with the involvement of a senior reviewer.

## Quality Assessment

We will assess risk of bias as part of data extraction by the same pairs of reviewers independently using the Cochrane risk-of-bias tool (RoB 2) for RCTs, which covers 5 domains: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcomes data (> 20% missing data will be considered a high risk of bias), bias in the measurement of the outcome, and reporting bias.<sup>47</sup>

We will also use the ROBINS-I tool for assessing risk of bias in nonrandomized studies. This tool covers 7 domains: bias due to confounding, bias in the selection of participants into the study, bias in classification of interventions, and bias due to deviations from the intended interventions, bias due to missing data, bias in the measurement of the outcome, and bias in selection of the reported result.<sup>48</sup>

## Data Analysis and Synthesis

For both research questions, the evidence synthesis team will narratively summarize and report effect estimates. Whenever possible, all continuous outcome measures that are reported as the mean difference and the associated 95% CI will be reported. For binary outcomes, the evidence synthesis team will aim to report baseline probability for the outcome, a measure of association (e.g., relative risk, OR, hazard ratio), and a corresponding 95% CI. The evidence synthesis team will aim to narratively synthesize findings across study types and outcome types. A quantitative meta-synthesis will not be conducted for any outcomes.

## **Opportunities for Stakeholder Feedback**

Stakeholders, including health care professionals, patients, drug manufacturers, and/or relevant associations will be given the opportunity to comment on the protocol, as well as to provide feedback on the draft report. Data identified as part of the feedback process may only be included if the source of data is in the public domain and fulfills the aforementioned selection criteria.

## **Areas for Potential Amendments**

If amendments are required at any time during the study, the reasons for the changes will be recorded in a study file and subsequently reported within the final study report. If necessary, a rescreening of the previous literature search or an updated literature search will be performed to capture additional data according to the amendments.

## References

1. Egan D, Fraifeld B, Trainum B. Opioid Use Disorder. American Psychiatric Association. Published December 2022. Accessed June 17, 2023. <https://www.psychiatry.org/patients-families/opioid-use-disorder#:~:text=Opioid%20Use%20Disorder%20Symptoms&text=Taking%20larger%20amounts%20or%20taking,or%20recovering%20from%20its%20effects.>
2. Centre for Addiction and Mental Health. *Opioid Agonist Therapy: A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder*; 2021.
3. Min JE, Pearce LA, Homayra F, et al. Estimates of opioid use disorder prevalence from a regression-based multi-sample stratified capture-recapture analysis. *Drug Alcohol Depend.* 2020;217:108337. [PubMed](#)
4. Belzak L, Halverson J. The opioid crisis in Canada: a national perspective. *Health Promot Chronic Dis Prev Can.* 2018;38(6):224-233. [PubMed](#)
5. Government of Canada. Opioid- and stimulant-related harms. Published June 26, 2023. Accessed July 12, 2023. <https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/graphs>
6. The Ontario Drug Policy Research Network, *Public Health Ontario, The Office of the Chief Coroner for Ontario / Ontario Forensic Pathology Service.* *Opioid Toxicity and Access to Treatment among Adolescents and Young Adults in Ontario.* ODPRN; 2023.
7. Friesen EL, Kurdyak PA, Gomes T, et al. The Impact of the COVID-19 Pandemic on Opioid-Related Harm in Ontario. Ontario COVID-19 Science Advisory Table; 2021. [doi:10.47326/ocsat.2021.02.42.1.0](https://doi.org/10.47326/ocsat.2021.02.42.1.0)
8. Chronic pain. Published June 12, 2023. Accessed June 20, 2023. <https://www.canada.ca/en/public-health/services/diseases/chronic-pain.html>
9. Delorme J, Kerckhove N, Authier N, Pereira B, Bertin C, Chenaf C. Systematic Review and Meta-Analysis of the Prevalence of Chronic Pain Among Patients With Opioid Use Disorder and Receiving Opioid Substitution Therapy. *J Pain.* 2023;24(2):192-203. [PubMed](#)
10. Edwards KA, Vowles KE, McHugh RK, Venner KL, Witkiewitz K. Changes in pain during buprenorphine maintenance treatment among patients with opioid use disorder and chronic pain. *J Consult Clin Psychol.* 2022;90(4):314-325. [PubMed](#)
11. Speed TJ, Parekh V, Coe W, Antoine D. Comorbid chronic pain and opioid use disorder: literature review and potential treatment innovations. *Int Rev Psychiatry.* 2018;30(5):136-146. [PubMed](#)
12. Dhingra L, Perlman DC, Masson C, et al. Longitudinal analysis of pain and illicit drug use behaviors in outpatients on methadone maintenance. *Drug Alcohol Depend.* 2015;149:285-289. [PubMed](#)
13. Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: Results from electronic health records data. *J Subst Abuse Treat.* 2017;77:26-30. [PubMed](#)
14. Carrière G, Garner R, Sanmartin C. Significant factors associated with problematic use of opioid pain relief medications among the household population, Canada, 2018. *Health Rep.* 2021;32(12):13-26. [PubMed](#)
15. Jones JD, Vogelmann JS, Luba R, Mumtaz M, Comer SD. Chronic pain and opioid abuse: Factors associated with health-related quality of life. *Am J Addict.* 2017;26(8):815-821. [PubMed](#)
16. Dhingra L, Masson C, Perlman DC, et al. Epidemiology of pain among outpatients in methadone maintenance treatment programs. *Drug Alcohol Depend.* 2013;128(1):161-165. [PubMed](#)
17. Barry DT, Cutter CJ, Beitel M, Kerns RD, Liong C, Schottenfeld RS. Psychiatric disorders among patients seeking treatment for co-occurring chronic pain and opioid use disorder. *J Clin Psychiatry.* 2016;77(10):13715. [PubMed](#)
18. Zhu Y, Mooney LJ, Yoo C, et al. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. *Drug Alcohol Depend.* 2021;228:108996. [PubMed](#)
19. Dennis BB, Bawor M, Naji L, et al. Impact of chronic pain on treatment prognosis for patients with opioid use disorder: a systematic review and meta-analysis. *Subst Abuse.* 2015;9:SART - S30120.
20. Jamison RN, Kauffman J, Katz NP. Characteristics of methadone maintenance patients with chronic pain. *J Pain Symptom Manage.* 2000;19(1):53-62. [PubMed](#)

21. Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. *Lancet*. 2019;393(10182):1760-1772. [PubMed](#)
22. Eibl JK, Morin K, Leinonen E, Marsh DC. The State of Opioid Agonist Therapy in Canada 20 Years after Federal Oversight. *Can J Psychiatry*. 2017;62(7):444-450. [PubMed](#)
23. Lazaridou A, Paschali M, Edwards RR, Gilligan C. Is Buprenorphine Effective for Chronic Pain? A Systematic Review and Meta-analysis. *Pain Med*. 2020;21(12):3691-3699. [PubMed](#)
24. of Physicians C, of Ontario. Methadone Program S. Methadone Maintenance Treatment Program Standards and Clinical Guidelines. College of Physicians and Surgeons of Ontario; 2011.
25. Guide P. VA/DoD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF SUBSTANCE USE DISORDERS. <https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGPatientSummaryFinal.pdf>
26. Handford C, Kahan M, Lester MD, Ordean A. *Buprenorphine/naloxone for Opioid Dependence: Clinical Practice Guideline*. Centre for Addiction and Mental Health; 2012.
27. Collaborating Centre for Mental Health N. Drug misuse: Opioid detoxification, The Nice Guideline. UK): National Institute for Health and Care Excellence: Guidelines. 2008.28. National Guideline Review Committee C. CRISM national guidelines for the clinical management of opioid use disorder. Canada: Canadian Research.
29. DeBar L, Mayhew M, Benes L, et al. A Primary Care-Based Cognitive Behavioral Therapy Intervention for Long-Term Opioid Users With Chronic Pain: A Randomized Pragmatic Trial. *Ann Intern Med*. 2021;175(1):46-55. [PubMed](#)
30. Barry DT, Beitel M, Cutter CJ, et al. An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain. *Drug Alcohol Depend*. 2018;194:460-467. [PubMed](#)
31. Garland EL, Hanley AW, Nakamura Y, et al. Mindfulness-Oriented Recovery Enhancement vs Supportive Group Therapy for Co-occurring Opioid Misuse and Chronic Pain in Primary Care: A Randomized Clinical Trial. *JAMA Intern Med*. 2022;182(4):407-417. [PubMed](#)
32. Nicol AL, Hurley RW, Benzon HT. Alternatives to Opioids in the Pharmacologic Management of Chronic Pain Syndromes: A Narrative Review of Randomized, Controlled, and Blinded Clinical Trials. *Anesth Analg*. 2017;125(5):1682-1703. [PubMed](#)
33. U. S. Department of Health a. . . Services. Managing Chronic Pain in Adults With Or in Recovery From Substance Use Disorders: Treatment Improvement Protocol Series (TIP 54). Lulu.com; 2013.
34. Busse JW, Wang L, Kamaleldin M, et al. Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. *JAMA*. 2018;320(23):2448-2460. [PubMed](#)
35. Duensing L, Eksterowicz N, Macario A, Brown M, Stern L, Ogonnaya A. Patient and physician perceptions of treatment of moderate-to-severe chronic pain with oral opioids. *Curr Med Res Opin*. 2010;26(7):1579-1585. [PubMed](#)
36. Goshua A, Craigie S, Guyatt GH, et al. Patient Values and Preferences Regarding Opioids for Chronic Noncancer Pain: A Systematic Review. *Pain Med*. 2018;19(12):2469-2480. [PubMed](#)
37. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T. *Cochrane handbook for systematic reviews of interventions*: John Wiley & Sons. Chichester, UK[Google].
38. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;4(1):1. [PubMed](#)
39. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Int J Surg*. 2021;88:105906. [PubMed](#)
40. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain*. 2008;9(2):105-121. [PubMed](#)
41. Reeves BC, Deeks JJ, Higgins JPT, Shea B, Tugwell P, Wells GA. Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors), ed. *Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023)*.



42. Zabor EC, Kaizer AM, Hobbs BP. Randomized Controlled Trials. *Chest*. 2020;158(1S):S79-S87. [PubMed](#)
43. Reddon H, Kerr T, Milloy MJ. Ranking evidence in substance use and addiction. *Int J Drug Policy*. 2020;83:102840. [PubMed](#)
44. Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. *CMAJ*. 2017;189(18):E659-E666. [PubMed](#)
45. Chou R, Hartung D, Turner J, Others. Opioid treatments for chronic pain: comparative effectiveness review, no. 229. Rockville, MD: Agency for Healthcare Research and Quality; 2020. AHRQ comparative effectiveness reviews (report no.: 20-EHC011).
46. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol*. 2016;75:40-46. [PubMed](#)
47. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:l4898. [PubMed](#)
48. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919. [PubMed](#)



## Appendix I: Literature Search Strategy

Note that this appendix has not been copy-edited.

### Database: Medline

1. (chronic adj4 pain\*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (76319)
2. Chronic Pain/ (16300)
3. exp Osteoarthritis/ (66436)
4. osteoarthritis\*.mp. (96448)
5. osteo-arthritis.mp. (391)
6. degenerative arthrit\*.mp. (1339)
7. exp Arthritis, Rheumatoid/ (115736)
8. exp Neuralgia/ (21418)
9. Diabetic Neuropathies/ (15017)
10. (neuropath\* adj5 (pain\* or diabet\*)).mp. (45703)
11. neuralg\*.mp. (29057)
12. zoster.mp. (21893)
13. Irritable Bowel Syndrome/ (7744)
14. (IBS or irritable colon or irritable bowel).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (17682)
15. Migraine Disorders/ (26132)
16. migraine.mp. (40639)
17. Fibromyalgia/ (8738)
18. fibromyalg\*.mp. (12427)
19. complex regional pain syndromes/ or exp causalgia/ or exp reflex sympathetic dystrophy/ (5637)
20. (complex regional pain syndromes or causalgia).mp. (2536)
21. Pain, Intractable/ (6238)
22. Phantom Limb/ (1922)
23. Hyperalgesia/ (12280)
24. ((noncancer\* or non-cancer\*or chronic\* or recurrent or persist\* or non-malign\*) adj3 pain).mp. (20349)
25. or/1-24 (447084)
26. exp back pain/ or exp failed back surgery syndrome/ or exp low back pain/ (40359)

27. Radiculopathy/ or radiculopathy.mp. (9652)
28. musculoskeletal pain/ or headache/ (32001)
29. exp Arthralgia/ (13915)
30. exp Headache Disorders/ (35578)
31. headache\*.mp. (98990)
32. Temporomandibular Joint Dysfunction Syndrome/ (4910)
33. ((TMJ or TMJD) and pain\*).mp. (2931)
34. whiplash.mp. or exp whiplash injury/ (4054)
35. exp Cumulative Trauma Disorders/ (14071)
36. exp Peripheral Nervous System Diseases/dt [Drug Therapy] (15402)
37. Pain Measurement/de [Drug Effects] (6801)
38. (backache\* or backpain\* or dorsalg\* or arthralgi\* or polyarthralgi\* or arthrodyni\* or myalgi\* or fibromyalgi\* or myodyni\* or neuralgi\* or ischialgi\* or crps or rachialgi\*).ab,ti. (48176)
39. ((back or discogen\* or bone or musculoskelet\* or muscle\* or skelet\* or spinal or spine or vertebra\* or joint\* or arthritis or Intestin\* or neuropath\* or neck or cervical\* or head or facial\* or complex or radicular or cervicobrachi\* or orofacial or somatic or shoulder\* or knee\* or hip or hips) adj3 pain).mp. (180190)
40. ((medication\* or opioid\* or opiate\* or narcotic\*) and pain).mp. (88068)
41. or/26-40 (427849)
42. (acute or emergency or preoperative or postoperative).ti,ab. (2068161)
43. 41 not 42 (345619) (Excluding acute pain)
44. 25 or 43 (666455) (Chronic pain (total))
45. exp Analgesics, Opioid/ (120400)
46. (opioid\* or opiate\*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (141323)
47. (alfentanil or alphaprodine or beta-casomorphin\$ or buprenorphine or carfentanil or codeine or deltorphin or dextromethorphan or dezocine or dihydrocodeine or dihydromorphine or enkephalin\$ or ethylketocyclazocine or ethylmorphine or etorphine or fentanyl or heroin or hydrocodone or hydromorphone or ketobemidone or levorphanol or lofentanil or meperidine or meptazinol or methadone or methadyl acetate or morphine or nalbuphine or opium or oxycodone or oxymorphone or pentazocine or phenazocine or phenoperidine or pirinitramide or promedol or propoxyphene or remifentanil or sufentanil or tilidine or tapentadol).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (159909)
48. or/45-47 (232170)
49. exp Narcotics/ (128525)
50. narcotic\*.mp. (62757)

51. (adolonta or Anpec or Ardinex or Asimadoline or Alvimopam or amadol or biodalgic or biokanol or Codinovo or contramal or Demerol or Dicodid or Dihydrocodeinone or dihydromorphinone or dihydrohydroxycodone or dihydrone or dilaudid or dinarkon or dolsin or dolosal or dolin or dolantin or dolargan or dolcontral or duramorph or duromorph or duragesic or durogesic or eucodal or Fedotzine or Fentanest or Fentora or Fortral or Hycodan or Hycon or Hydrocodone or Hydrocodeinonebitartrate or hydromorphon or hydroxycodone or isocodeine or isonipeccain or jutadol or laudacon or l dromoran or levodroman or levorphan or levo-dromoran or levodromoran or lexic or lidol or lydol or morfin or morfina or morphia or morphin or morphinium or morphinene or morphium or ms contin or n-methylmorphine or n methylmorphine or nobligan or numorphan or oramorph or oxycodone or oxiconum or oxycone or oxycontin or palladone or pancodine or pethidine or phentanyl or prontosfort or robidone or skenan or sublimaze or sulfentanyl or sulfentanil or sufenta or takadol or talwin or theocodin or tramadol or tramadolhameln or tramadol or tramadura or tramagetic or tramagit or tramake or tramal or tramex or tramundin or trasedal or theradol or tiral or topalgic or tradol or tradolpuren or tradonal or tralgiol or tramadorsch or tramadin or tramadoc or ultram or zamudol or zumalgic or zydol or zytram).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (11346)
52. or/45-51 (263279)
53. exp Prescription Drug Misuse/ (14308)
54. exp opioid-related disorders/ (28351)
55. "Drug and Narcotic Control"/ (8870)
56. substance abuse detection/ (9661)
57. Drug Utilization/sn (6668)
58. Inappropriate Prescribing/sn (1437)
59. or/53-58
60. Drug-Seeking Behavior/ (1426)
61. Behavior, Addictive/ (10556)
62. Substance Withdrawal Syndrome/ (21635)
63. Poisoning/ (22498)
64. "Drug-Related Side Effects and Adverse Reactions"/ (33499)
65. accidents/ or accidental falls/ or accidents, traffic/ (85369)
66. substance-related disorders/ (97656)
67. Opioid-Related Disorders/ (16439)
68. or/ 60-67
69. (Opioid\* or opiate\* or narcotic\* or analges\* or prescription\*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (407327)
70. 68 and 69 (SUD limit to opioid)

71. ((Opioid\* or opiate\* or narcotic\* or analges\* or prescription\*) adj3 (abuse or addict\* or misuse or overdose or poison\* or diversion or aberrant or monitoring or mortality or death or suicide or coroner or (prob\* adj2 "drug use"))).mp. (18172)
72. (behav\* adj3 (nonmedical or nontherapeutic or aberrant)).mp. (30)
73. 59 or 70 or 72 or 73 (Total SUD & OUD)
74. (systematic review or meta-analysis).pt. (316513)
75. meta-analysis/ or systematic review/ or systematic reviews as topic/ or meta-analysis as topic/ or "meta analysis (topic)"/ or "systematic review (topic)"/ or exp technology assessment, biomedical/ or network meta-analysis/ (354883)
76. ((systematic\* adj3 (review\* or overview\*)) or (methodologic\* adj3 (review\* or overview\*))).ti,ab,kf. (322785)
77. ((quantitative adj3 (review\* or overview\* or synthes\*)) or (research adj3 (integrati\* or overview\*))).ti,ab,kf. (15730)
78. ((integrative adj3 (review\* or overview\*)) or (collaborative adj3 (review\* or overview\*)) or (pool\* adj3 analy\*)).ti,ab,kf. (39038)
79. (data synthes\* or data extraction\* or data abstraction\*).ti,ab,kf. (40704)
80. (handsearch\* or hand search\*).ti,ab,kf. (11169)
81. (mantel haenszel or peto or der simonian or dersimonian or fixed effect\* or latin square\*).ti,ab,kf. (35833)
82. (met analy\* or metanaly\* or technology assessment\* or HTA or HTAs or technology overview\* or technology appraisal\*).ti,ab,kf. (12195)
83. (meta regression\* or metaregression\*).ti,ab,kf. (14653)
84. (meta-analy\* or metaanaly\* or systematic review\* or biomedical technology assessment\* or bio-medical technology assessment\*).mp,hw. (470110)
85. (medline or cochrane or pubmed or medlars or embase or cinahl).ti,ab,hw. (343797)
86. (cochrane or (health adj2 technology assessment) or evidence report).jw. (21497)
87. (comparative adj3 (efficacy or effectiveness)).ti,ab,kf. (17617)
88. (outcomes research or relative effectiveness).ti,ab,kf. (11256)
89. ((indirect or indirect treatment or mixed-treatment or bayesian) adj3 comparison\*).ti,ab,kf. (4342)
90. [(meta-analysis or systematic review).md.] (0)
91. (multi\* adj3 treatment adj3 comparison\*).ti,ab,kf. (295)
92. (mixed adj3 treatment adj3 (meta-analy\* or metaanaly\*)).ti,ab,kf. (179)
93. umbrella review\*.ti,ab,kf. (1519)
94. (multi\* adj2 paramet\* adj2 evidence adj2 synthesis).ti,ab,kf. (14)
95. (multiparamet\* adj2 evidence adj2 synthesis).ti,ab,kf. (18)
96. (multi-paramet\* adj2 evidence adj2 synthesis).ti,ab,kf. (12)
97. or/75-97

98. exp clinical pathway/ (7805)
99. exp clinical protocol/ (190093)
100. clinical protocols/ (29902)
101. exp consensus/ (20898)
102. exp consensus development conference/ (12660)
103. exp consensus development conferences as topic/ (3000)
104. critical pathways/ (7805)
105. exp guideline/ (37781)
106. guidelines as topic/ (42069)
107. exp practice guideline/ (30519)
108. practice guidelines as topic/ (127541)
109. health planning guidelines/ (4165)
110. exp treatment guidelines/ (0)
111. Clinical Decision Rules/ (921)
112. (guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt. (47682)
113. (position statement\* or policy statement\* or practice parameter\* or best practice\*).ti,ab,kf. (46552)
114. (standards or guideline or guidelines).ti,kf. (136133)
115. ((practice or treatment\* or clinical) adj guideline\*).ab. (53112)
116. (CPG or CPGs).ti. (6449)
117. consensus\*.ti,kf. (35112)
118. consensus\*.ab. /freq=2 (34429)
119. ((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol\*)).ti,ab,kf. (26765)
120. recommendat\*.ti,kf. or guideline recommendation\*.ab. (58820)
121. (care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf. (84255)
122. (algorithm\* adj2 (screening or examination or test or tested or testing or assessment\* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab,kf. (10236)
123. (algorithm\* adj2 (pharmacotherap\* or chemotherap\* or chemotreatment\* or therap\* or treatment\* or intervention\*)).ti,ab,kf. (12928)
124. (guideline\* or standards or consensus\* or recommendat\*).au. (10)
125. [(guideline\* or standards or consensus\* or recommendat\*).co.] (0)
126. (guideline\* or standards or consensus\* or recommendat\*).ca. (1612)
127. or/99-127
128. Epidemiologic Methods/ (31616)
129. exp Epidemiologic Studies/ (3149024)

130. Observational Studies as Topic/ (8885)
131. Clinical Studies as Topic/ (789)
132. single-case studies as topic/ (98)
133. (Observational Study or Validation Studies or Clinical Study).pt. (149473)
134. (observational adj3 (study or studies or design or analysis or analyses)).ti,ab,kf. (221753)
135. cohort\*.ti,ab,kf. (863693)
136. (prospective adj7 (study or studies or design or analysis or analyses)).ti,ab,kf. (535035)
137. ((follow up or followup) adj7 (study or studies or design or analysis or analyses)).ti,ab,kf. (170303)
138. ((longitudinal or longterm or (long adj term)) adj7 (study or studies or design or analysis or analyses or data)).ti,ab,kf. (347817)
139. (retrospective adj7 (study or studies or design or analysis or analyses or data or review)).ti,ab,kf. (685036)
140. ((case adj control) or (case adj comparison) or (case adj controlled)).ti,ab,kf. (159981)
141. (case-referent adj3 (study or studies or design or analysis or analyses)).ti,ab,kf. (638)
142. (population adj3 (study or studies or analysis or analyses)).ti,ab,kf. (234296)
143. (descriptive adj3 (study or studies or design or analysis or analyses)).ti,ab,kf. (110009)
144. ((multidimensional or (multi adj dimensional)) adj3 (study or studies or design or analysis or analyses)).ti,ab,kf. (4984)
145. (cross adj sectional adj7 (study or studies or design or research or analysis or analyses or survey or findings)).ti,ab,kf. (439128)
146. ((natural adj experiment) or (natural adj experiments)).ti,ab,kf. (3321)
147. (quasi adj (experiment or experiments or experimental)).ti,ab,kf. (20541)
148. ((non experiment or nonexperiment or non experimental or nonexperimental) adj3 (study or studies or design or analysis or analyses)).ti,ab,kf. (1719)
149. (prevalence adj3 (study or studies or analysis or analyses)).ti,ab,kf. (49797)
150. case series.ti,ab,kf. (103877)
151. case reports.pt. (2346603)
152. (case adj3 (report or reports or study or studies or histories)).ti,ab,kf. (983691)
153. organizational case studies/ (12631)
154. or/129-154
155. 98 or 124 or 155
156. 44 AND 52 AND 74 AND 156
157. animals/ not humans/ (4791092)
158. exp Animals, Laboratory/ (901737)
159. exp Animal Experimentation/ (9684)
160. exp Models, Animal/ (592322)

161. exp Rodentia/ (3309846)
162. (rat or rats or mouse or mice).ti. (1363634)
163. or/157-162
164. 156 not 163

#### Database: Embase

1. (chronic adj4 pain\*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (125002)
2. chronic pain/ (65194)
3. exp osteoarthritis/ (136551)
4. osteoarthritis\*.mp. (153027)
5. osteo-arthritis.mp. (440)
6. degenerative arthritis\*.mp. (1613)
7. exp rheumatoid arthritis/ (209398)
8. exp neuralgia/ (110015)
9. diabetic neuropathy/ (24878)
10. (neuropath\* adj5 (pain\* or diabet\*)).mp. (80274)
11. neuralg\*.mp. (31802)
12. zoster.mp. (40221)
13. irritable colon/ (27468)
14. (Irritable Bowel Syndrome or IBS).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (26916)
15. exp migraine/ (66654)
16. migraine.mp. (73757)
17. fibromyalgia/ (21472)
18. fibromyalg\*.mp. (23329)
19. reflex sympathetic dystrophy.mp. (2367)
20. (complex regional pain syndromes or causalgia).mp. (1315)
21. intractable pain/ (5012)
22. phantom limb.mp. or agnosia/ or phantom pain/ or amputation stump/ (7866)
23. hyperalgesia/ (19693)
24. ((noncancer\* or non-cancer\* or chronic\* or recurrent or persist\* or non-malign\*) adj3 pain).mp. (30190)
25. or/1-24 (775064)
26. exp backache/ (115864)

27. radiculopathy.mp. or exp radiculopathy/ (40963)
28. musculoskeletal pain/ (12033)
29. exp arthralgia/ (64906)
30. headache/ (226226)
31. headache\*.mp. (292451)
32. temporomandibular joint disorder/ (14501)
33. ((TMJ or TMJD) and pain\*).mp. (3994)
34. whiplash.mp. or whiplash injury/ (5059)
35. exp cumulative trauma disorder/ (21894)
36. ((medication\* or opioid\* or opiate\* or narcotic\*) and pain).mp. (154398)
37. or/26-36 (642738)
38. (acute or emergency or preoperative or postoperative).ti,ab. (2826723)
39. 37 not 38 (517733)
40. 25 or 39 (1146023)
41. exp narcotic analgesic agent/ (347645)
42. (opioid\* or opiate\*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (211666)
43. (alfentanil or alphaprodine or beta-casomorphin\$ or buprenorphine or carfentanil or codeine or deltorphin or dextromethorphan or dezocine or dihydrocodeine or dihydromorphine or enkephalin\$ or ethylketocyclazocine or ethylmorphine or etorphine or fentanyl or heroin or hydrocodone or hydromorphone or ketobemidone or levorphanol or lofentanil or meperidine or meptazinol or methadone or methadyl acetate or morphine or nalbuphine or opium or oxycodone or oxymorphone or pentazocine or phenazocine or phenoperidine or pirinitramide or promedol or propoxyphene or remifentanil or sufentanil or tilidine or tapentadol).mp. (298666)
44. (adolonta or Anpec or Ardinex or Asimadoline or Alvimopam or amadol or biodalgic or biokanol or Codinovo or contramal or Demerol or Dicotid or Dihydrocodeinone or dihydromorphinone or dihydrohydroxycodone or dihydrone or dilaudid or dinarkon or dolsin or dolosal or dolin or dolantin or dolargan or dolcontral or duramorph or duromorph or duragesic or durogesic or eucodal or Fedotzine or Fentanest or Fentora or Fortral or Hycodan or Hycon or Hydrocodone or Hydrocodeinonebitartrate or hydromorphon or hydroxycodone or isocodeine or isonipecaïn or jutadol or laudacon or l dromoran or levodroman or levorphan or levo-dromoran or levodromoran or lexic or lidol or lydol or morfin or morfine or morphia or morphin or morphinium or morphinene or morphium or ms contin or n-methylmorphine or n methylmorphine or nobligan or numorphan or oramorph or oxycodone or oxiconum or oxycone or oxycontin or palladone or pancodine or pethidine or phentanyl or prontofort or robidone or skenan or sublimaze or sulfentanyl or sulfentanil or sufenta or takadol or talwin or theocodin or tramadol or tramadolhameln or tramadolor or tramadura or tramagetic or tramagit or tramake or tramal or tramex or tramundin or trasedal or theradol or tiral or topalgic or tradol or tradolpuren or tradonal or tralgiol or tramadorsch or tramadin or tramadoc or ultram or zamudol or zumalgic or zydol or zytram).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (54623)
45. or/41-44 (440589)



46. opiate addiction/ (22619)
47. narcotic dependence/ or morphine addiction/ (4331)
48. prescription drug diversion/ (370)
49. or/46-48
50. drug abuse/ or analgesic agent abuse/ or drug misuse/ (61308)
51. drug control/ (11726)
52. drug monitoring/ (54894)
53. substance abuse/ (54984)
54. drug urine level/ (32300)
55. drug dose regimen/ (35206)
56. drug overdose/ (30250)
57. drug seeking behavior/ (2717)
58. drug dependence/ (58023)
59. addiction/ (48322)
60. drug withdrawal/ (210460)
61. withdrawal syndrome/ (29140)
62. intoxication/ (179248)
63. accident/ or falling/ or home accident/ or traffic accident/ (126306)
64. suicide/ or suicidal behavior/ or suicide attempt/ (93381)
65. or/50-64
66. (Opioid\* or opiate\* or narcotic\* or analges\* or prescription\*).ti,ab. (464941)
67. 65 and 69
68. ((Opioid\* or opiate\* or narcotic\* or analges\* or prescription\*) adj3 (abuse or addict\* or misuse or overdose or poison\* or diversion or aberrant or monitoring or mortality or death or suicide or coroner or (prob\* adj2 "drug use"))).mp. (40929)
69. 49 or 67 or 68
70. observational study/
71. cohort analysis/
72. longitudinal study/
73. follow up/
74. retrospective study/
75. exp case control study/
76. cross-sectional study/
77. quasi experimental study/
78. prospective study/

79. (observational adj3 (study or studies or design or analysis or analyses)).ti,ab,kf.
80. cohort\*.ti,ab,kf.
81. (prospective adj7 (study or studies or design or analysis or analyses)).ti,ab,kf.
82. ((follow up or followup) adj7 (study or studies or design or analysis or analyses)).ti,ab,kf.
83. ((longitudinal or longterm or (long adj term)) adj7 (study or studies or design or analysis or analyses or data)).ti,ab,kf.
84. (retrospective adj7 (study or studies or design or analysis or analyses or data or review)).ti,ab,kf.
85. ((case adj control) or (case adj comparison) or (case adj controlled)).ti,ab,kf.
86. (case-referent adj3 (study or studies or design or analysis or analyses)).ti,ab,kf.
87. (population adj3 (study or studies or analysis or analyses)).ti,ab,kf.
88. (descriptive adj3 (study or studies or design or analysis or analyses)).ti,ab,kf.
89. ((multidimensional or (multi adj dimensional)) adj3 (study or studies or design or analysis or analyses)).ti,ab,kf.
90. (cross adj sectional adj7 (study or studies or design or research or analysis or analyses or survey or findings)).ti,ab,kf.
91. ((natural adj experiment) or (natural adj experiments)).ti,ab,kf.
92. (quasi adj (experiment or experiments or experimental)).ti,ab,kf.
93. ((non experiment or nonexperiment or non experimental or nonexperimental) adj3 (study or studies or design or analysis or analyses)).ti,ab,kf.
94. (prevalence adj3 (study or studies or analysis or analyses)).ti,ab,kf.
95. case series.ti,ab,kf.
96. case study/
97. case report/
98. (case adj3 (report or reports or study or studies or histories)).ti,ab,kf.
99. or/70-98
100. (systematic review or meta-analysis).pt.
101. meta-analysis/ or systematic review/ or systematic reviews as topic/ or meta-analysis as topic/ or "meta analysis (topic)"/ or "systematic review (topic)"/ or exp technology assessment, biomedical/ or network meta-analysis/
102. ((systematic\* adj3 (review\* or overview\*)) or (methodologic\* adj3 (review\* or overview\*))).ti,ab,kf.
103. ((quantitative adj3 (review\* or overview\* or synthes\*)) or (research adj3 (integrati\* or overview\*))).ti,ab,kf.
104. ((integrative adj3 (review\* or overview\*)) or (collaborative adj3 (review\* or overview\*)) or (pool\* adj3 analy\*)).ti,ab,kf.
105. (data synthes\* or data extraction\* or data abstraction\*).ti,ab,kf.
106. (handsearch\* or hand search\*).ti,ab,kf.
107. (mantel haenszel or peto or der simonian or dersimonian or fixed effect\* or latin square\*).ti,ab,kf.

108. (met analy\* or metanaly\* or technology assessment\* or HTA or HTAs or technology overview\* or technology appraisal\*).ti,ab,kf.
109. (meta regression\* or metaregression\*).ti,ab,kf.
110. (meta-analy\* or metaanaly\* or systematic review\* or biomedical technology assessment\* or bio-medical technology assessment\*).mp,hw.
111. (medline or cochrane or pubmed or medlars or embase or cinahl).ti,ab,hw.
112. (cochrane or (health adj2 technology assessment) or evidence report).jw.
113. (comparative adj3 (efficacy or effectiveness)).ti,ab,kf.
114. (outcomes research or relative effectiveness).ti,ab,kf.
115. ((indirect or indirect treatment or mixed-treatment or bayesian) adj3 comparison\*).ti,ab,kf.
116. (meta-analysis or systematic review).md.
117. (multi\* adj3 treatment adj3 comparison\*).ti,ab,kf.
118. (mixed adj3 treatment adj3 (meta-analy\* or metaanaly\*)).ti,ab,kf.
119. umbrella review\*.ti,ab,kf.
120. (multi\* adj2 paramet\* adj2 evidence adj2 synthesis).ti,ab,kf.
121. (multiparamet\* adj2 evidence adj2 synthesis).ti,ab,kf.
122. (multi-paramet\* adj2 evidence adj2 synthesis).ti,ab,kf.
123. or/100-122
124. exp clinical pathway/
125. exp clinical protocol/
126. clinical protocols/
127. exp consensus/
128. exp consensus development conference/
129. exp consensus development conferences as topic/
130. critical pathways/
131. exp guideline/
132. guidelines as topic/
133. exp practice guideline/
134. practice guidelines as topic/
135. health planning guidelines/
136. exp treatment guidelines/
137. Clinical Decision Rules/
138. (guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt.
139. (position statement\* or policy statement\* or practice parameter\* or best practice\*).ti,ab,kf.

140. (standards or guideline or guidelines).ti,kf.
141. ((practice or treatment\* or clinical) adj guideline\*).ab.
142. (CPG or CPGs).ti.
143. consensus\*.ti,kf.
144. consensus\*.ab. /freq=2
145. ((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol\*)).ti,ab,kf.
146. recommendat\*.ti,kf. or guideline recommendation\*.ab.
147. (care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf.
148. (algorithm\* adj2 (screening or examination or test or tested or testing or assessment\* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab,kf.
149. (algorithm\* adj2 (pharmacotherap\* or chemotherap\* or chemotreatment\* or therap\* or treatment\* or intervention\*)).ti,ab,kf.
150. (guideline\* or standards or consensus\* or recommendat\*).au.
151. (guideline\* or standards or consensus\* or recommendat\*).co.
152. (guideline\* or standards or consensus\* or recommendat\*).ca.
153. or/124-153
154. 99 or 123 or 153
155. 40 AND 45 AND 69 AND 154
156. exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/ (28918360)
157. human/ or normal human/ or human cell/ (22322879)
158. animals/ not humans/ (983946)
159. nonhuman/ (6525527)
160. exp Animal Experiment/ (2687886)
161. exp Experimental Animal/ (714449)
162. exp Rodent/ (3671555)
163. (rat or rats or mouse or mice).ti. (1502232)
164. or/ 156-165 (Non-Human concept)
165. 155 NOT 166 (Final results)

#### Database: PsycINFO

1. (chronic adj4 pain\*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (23905)
2. chronic pain/ (14179)
3. exp arthritis/ (4366)

4. osteoarthritis.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (2287)
5. osteo-arthritis.mp. (8)
6. degenerative arthritis.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (15)
7. exp neuralgia/ (973)
8. exp neuropathy/ (6475)
9. (neuropath\* adj5 (pain\* or diabet\*)).mp. (7288)
10. neuralg\*.mp. (3464)
11. zoster.mp. (598)
12. irritable bowel syndrome/ (1210)
13. (IBS or irritable colon or irritable bowel).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (2108)
14. migraine headache/ (9426)
15. migraine.mp. (12623)
16. fibromyalgia/ (2112)
17. fibromyalg\*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (3615)
18. complex regional pain syndromes.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (323)
19. "complex regional pain syndrome (type i)"/ (174)
20. (complex regional pain syndromes or causalgia).mp. (413)
21. somatosensory disorders/ (1493)
22. hyperalgesi\*.mp. (5579)
23. somatoform pain disorder/ (850)
24. somatoform disorders/ (7886)
25. conversion disorder/ (1075)
26. ((noncancer\* or non-cancer\*or chronic\* or recurrent or persist\* or non-malign\*) adj3 pain).mp. (3566)
27. or/1-26 (67174)
28. back pain.mp. or exp Back Pain/ (6448)
29. radiculopathy.mp. (348)
30. musculoskeletal pain.mp. (1912)
31. Arthralgia.mp. (337)
32. headache.mp. or exp HEADACHE/ (21143)
33. ((TMJ or TMJD) and pain\*).mp. (158)

34. WHIPLASH/ or whiplash.mp. (616)
35. (backache\* or backpain\* or dorsalg\* or arthralgi\* or polyarthralgi\* or arthrodyni\* or myalgi\* or fibromyalgi\* or myodyn\* or neuralgi\* or ischialgi\* or crps or rachialgi\*).ab,ti. (6240)
36. ((back or discogen\* or bone or musculoskelet\* or muscle\* or skelet\* or spinal or spine or vertebra\* or joint\* or arthritis or Intestin\* or neuropath\* or neck or cervical\* or head or facial\* or complex or radicular or cervicobrachi\* or orofacial or somatic or shoulder\* or knee\* or hip or hips) adj3 pain).mp. (22027)
37. ((medication\* or opioid\* or opiate\* or narcotic\*) and pain).mp. (15283)
38. or/28-37 (57700)
39. (acute or emergency or preoperative or postoperative).ti,ab. (128922)
40. 38 not 39 (50357)
41. 27 or 40 (88522)
42. exp opiates/ (27037)
43. (opioid\* or opiate\*).mp. (35096)
44. (alfentanil or alphaprodine or beta-casomorphin\$ or buprenorphine or carfentanil or codeine or deltorphin or dextromethorphan or dezocine or dihydrocodeine or dihydromorphine or enkephalin\$ or ethylketocyclazocine or ethylmorphine or etorphine or fentanyl or heroin or hydrocodone or hydromorphone or ketobemidone or levorphanol or lofentanil or meperidine or meptazinol or methadone or methadyl acetate or morphine or nalbuphine or opium or oxycodone or oxymorphone or pentazocine or phenazocine or phenoperidine or pirinitramide or promedol or propoxyphene or remifentanil or sufentanil or tilidine or tapentadol).mp. (32725)
45. exp narcotic drugs/ (31229)
46. narcotic\*.mp. (12271)
47. (adolonta or Anpec or Ardinex or Asimadoline or Alvimopam or amadol or biodalgic or biokanol or Codinovo or contramal or Demerol or Dicodeid or Dihydrocodeinone or dihydromorphinone or dihydrohydroxycodone or dihydrone or dilaudid or dinarkon or dolsin or dolosal or dolin or dolantin or dolargan or dolcontral or duramorph or duromorph or duragesic or durogesic or eucodal or Fedotzine or Fentanest or Fentora or Fortral or Hycodan or Hycon or Hydrocodone or Hydrocodeinonebitartrate or hydromorphon or hydroxycodone or isocodeine or isonipecain or jutadol or laudacon or l dromoran or levodroman or levorphan or levo-dromoran or levodromoran or lexir or lidol or lydol or morfin or morfine or morphia or morphin or morphinium or morphinene or morphium or ms contin or n-methylmorphine or n methylmorphine or nobligan or numorphan or oramorph or oxycodone or oxiconum or oxycone or oxycontin or palladone or pancodine or pethidine or phentanyl or prontosfort or robidone or skenan or sublimaze or sulfentanyl or sulfentanil or sufenta or takadol or talwin or theocodin or tramadol or tramadolhameln or tramadol or tramadura or tramagetic or tramagit or tramake or tramal or tramex or tramundin or trasedal or theradol or tiral or topalgic or tradol or tradolpuren or tradonal or tralgiole or tramadorsch or tramadin or tramadoc or ultram or zamudol or zumalgic or zydol or zytram).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (1124)
48. or/42-47 (57076)
49. drug dependency/ (12925)
50. drug abuse/ (47752)
51. drug rehabilitation/ (21752)

52. "substance use disorder"/ (8448)
53. self-medication/ (718)
54. prescription drugs/ (5147)
55. drug overdoses/ (2091)
56. exp drug addiction/ (19576)
57. drug seeking/ (1063)
58. addiction/ (11648)
59. drug withdrawal/ (5960)
60. toxic disorders/ (1561)
61. "side effects (drug)"/ (26415)
62. drug tolerance/ (4601)
63. exp accidents/ (14353)
64. exp "death and dying"/ (41493)
65. suicide/ or self-destructive behavior/ or attempted suicide/ or self-injurious behavior/ or suicidal ideation/ or suicide prevention/ (47617)
66. or/49-65
67. (Opioid\* or opiate\* or narcotic\* or analges\* or prescription\*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (72778)
68. 67 AND 68
69. ((Opioid\* or opiate\* or narcotic\* or analges\* or prescription\*) adj3 (abuse or addict\* or misuse or overdose or poison\* or diversion or aberrant or monitoring or mortality or death or suicide or coroner or (prob\* adj2 "drug use"))).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (8489)
70. 69 OR 71
71. cohort analysis/ (1699)
72. longitudinal studies/ (16107)
73. prospective studies/ (1312)
74. retrospective studies/ (934)
75. followup studies/ (12397)
76. quasi experimental methods/ (506)
77. (observational adj3 (study or studies or design or analysis or analyses)).ti,ab. (18927)
78. cohort\*.ti,ab. (97823)
79. (prospective adj7 (study or studies or design or analysis or analyses)).ti,ab. (46322)
80. ((follow up or followup) adj7 (study or studies or design or analysis or analyses)).ti,ab. (32999)
81. ((longitudinal or longterm or (long adj term)) adj7 (study or studies or design or analysis or analyses or data))

82. (retrospective adj7 (study or studies or design or analysis or analyses or data or review)).ti,ab. (31208)
83. ((case adj control) or (case adj comparison) or (case adj controlled)).ti,ab. (13337)
84. (case-referent adj3 (study or studies or design or analysis or analyses)).ti,ab. (20)
85. (population adj3 (study or studies or analysis or analyses)).ti,ab. (33516)
86. (descriptive adj3 (study or studies or design or analysis or analyses)).ti,ab. (33476)
87. ((multidimensional or (multi adj dimensional)) adj3 (study or studies or design or analysis or analyses)).ti,ab.
88. (cross adj sectional adj7 (study or studies or design or research or analysis or analyses or survey or findings))
89. ((natural adj experiment) or (natural adj experiments)).ti,ab. (1570)
90. (quasi adj (experiment or experiments or experimental)).ti,ab. (15846)
91. ((non experiment or nonexperiment or non experimental or nonexperimental) adj3 (study or studies or design or ana
92. (prevalence adj3 (study or studies or analysis or analyses)).ti,ab. (9727)
93. case series.ti,ab. (4888)
94. (case adj3 (report or reports or study or studies or histories)).ti,ab. (168186)
95. case report/ (23364)
96. or/1-25 (621735)
97. (systematic review or meta-analysis).pt. (0)
98. meta-analysis/ or systematic review/ or systematic reviews as topic/ or meta-analysis as topic/ or "meta analysis
99. [((systematic\* adj3 (review\* or overview\*)) or (methodologic\* adj3 (review\* or overview\*))).ti,ab,kf.] (0)
100. [(((quantitative adj3 (review\* or overview\* or synthes\*)) or (research adj3 (integrati\* or overview\*))).ti,ab,kf.]
101. [(((integrative adj3 (review\* or overview\*)) or (collaborative adj3 (review\* or overview\*)) or (pool\* adj3 analy\*))
102. [(data synthes\* or data extraction\* or data abstraction\*).ti,ab,kf.] (0)
103. [(handsearch\* or hand search\*).ti,ab,kf.] (0)
104. [(mantel haenszel or peto or der simonian or dersimonian or fixed effect\* or latin square\*).ti,ab,kf.] (0)
105. [(met analy\* or metanaly\* or technology assessment\* or HTA or HTAs or technology overview\* or technology appraisa
106. [(meta regression\* or metaregression\*).ti,ab,kf.] (0)
107. (meta-analy\* or metaanaly\* or systematic review\* or biomedical technology assessment\* or bio-medical technology a
108. (medline or cochrane or pubmed or medlars or embase or cinahl).ti,ab,hw. (35940)
109. (cochrane or (health adj2 technology assessment) or evidence report).jw. (0)
110. [(comparative adj3 (efficacy or effectiveness)).ti,ab,kf.] (0)
111. [(outcomes research or relative effectiveness).ti,ab,kf.] (0)
112. [(((indirect or indirect treatment or mixed-treatment or bayesian) adj3 comparison\*).ti,ab,kf.] (0)



113. (meta-analysis or systematic review).md. (64233)
114. [(multi\* adj3 treatment adj3 comparison\*).ti,ab,kf.] (0)
115. [(mixed adj3 treatment adj3 (meta-analy\* or metaanaly\*)).ti,ab,kf.] (0)
116. [umbrella review\*.ti,ab,kf.] (0)
117. [(multi\* adj2 paramet\* adj2 evidence adj2 synthesis).ti,ab,kf.] (0)
118. [(multiparamet\* adj2 evidence adj2 synthesis).ti,ab,kf.] (0)
119. [(multi-paramet\* adj2 evidence adj2 synthesis).ti,ab,kf.] (0)
120. or/27-49 (104270)
121. exp clinical pathway/ (0)
122. exp clinical protocol/ (0)
123. clinical protocols/ (0)
124. exp consensus/ (0)
125. exp consensus development conference/ (0)
126. exp consensus development conferences as topic/ (0)
127. critical pathways/ (0)
128. exp guideline/ (0)
129. guidelines as topic/ (0)
130. exp practice guideline/ (0)
131. practice guidelines as topic/ (0)
132. health planning guidelines/ (0)
133. exp treatment guidelines/ (9284)
134. Clinical Decision Rules/ (0)
135. (guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt
136. [(position statement\* or policy statement\* or practice parameter\* or best practice\*).ti,ab,kf.] (0)
137. [(standards or guideline or guidelines).ti,kf.] (0)
138. ((practice or treatment\* or clinical) adj guideline\*).ab. (9192)
139. (CPG or CPGs).ti. (140)
140. [consensus\*.ti,kf.] (0)
141. consensus\*.ab. /freq=2 (5795)
142. [((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol\*)).ti,ab,kf.] (0)
143. [recommendat\*.ti,kf. or guideline recommendation\*.ab.] (0)
144. [(care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf.] (0)

145. [(algorithm\* adj2 (screening or examination or test or tested or testing or assessment\* or diagnosis or diagnoses
146. [(algorithm\* adj2 (pharmacotherap\* or chemotherap\* or chemotreatment\* or therap\* or treatment\* or intervention\*))
147. (guideline\* or standards or consensus\* or recommendat\*).au. (0)
148. (guideline\* or standards or consensus\* or recommendat\*).co. (0)
149. (guideline\* or standards or consensus\* or recommendat\*).ca. (299)
150. or/51-79 (21794)
151. 97 or 121 or 151
152. 41 AND 48 AND 71 AND 152

### Database: CINAHL

#### # Query

- S75 S43 AND S51 AND S57 AND S74
- S74 S72 AND S73
- S73 Opioid\* or opiate\* or narcotic\* or analges\* or prescription\*
- S72 S58 OR S59 OR S60 OR S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71
- S71 (MH "Suicide+")
- S70 (MH "Death+")
- S69 (MH "Accidents") OR (MH "Accidental Falls") OR (MH "Accidents, Home") OR (MH "Accidents, Traffic")
- S68 (MH "Adverse Drug Event+")
- S67 (MH "Poisoning")
- S66 (MH "Substance Withdrawal Syndrome")
- S65 (MH "Behavior, Addictive")
- S64 (MH "Substance Abuse Detection")
- S63 (MH "Drug and Narcotic Control")
- S62 (MH "Drug Toxicity")
- S61 (MH "Overdose")
- S60 (MH "Substance Use Disorders")
- S59 (MH "Substance Dependence")
- S58 (MH "Substance Abuse")
- S57 S52 OR S53 OR S54 OR S55 OR S56
- S56 (TI "case series" OR AB "case series") OR ((TI case OR AB case) N3 ((TI report OR AB report) OR (TI reports OR AB reports) OR (TI study OR AB study) OR (TI studies OR AB studies) OR (TI histories OR AB histories))) OR MH ("case studies")
- S55 ((TI cross OR AB cross) W1 (TI sectional OR AB sectional) N7 ((TI study OR AB study) OR (TI studies OR AB studies) OR (TI design OR AB design) OR (TI research OR AB research) OR (TI analysis OR AB analysis) OR (TI analyses OR AB analyses) OR (TI survey OR AB survey) OR (TI findings OR AB findings))) OR (((TI natural OR

- AB natural) W1 (TI experiment OR AB experiment)) OR ((TI natural OR AB natural) W1 (TI experiments OR AB experiments))) OR ((TI quasi OR AB quasi) W1 ((TI experiment OR AB experiment) OR (TI experiments OR AB experiments) OR (TI experimental OR AB experimental))) OR (((TI "non experiment" OR AB "non experiment") OR (TI nonexperiment OR AB nonexperiment) OR (TI "non experimental" OR AB "non experimental") OR (TI nonexperimental OR AB nonexperimental)) N3 ((TI study OR AB study) OR (TI studies OR AB studies) OR (TI design OR AB design) OR (TI analysis OR AB analysis) OR (TI analyses OR AB analyses))) OR ((TI prevalence OR AB prevalence) N3 ((TI study OR AB study) OR (TI studies OR AB studies) OR (TI analysis OR AB analysis) OR (TI analyses OR AB analyses)))
- S54 MH "Nonexperimental Studies+" OR (MH "Correlational Studies") OR (MH "Control Group") OR (MH "Matched-Pair Analysis") OR ((TI observational OR AB observational) N3 ((TI study OR AB study) OR (TI studies OR AB studies) OR (TI design OR AB design) OR (TI analysis OR AB analysis) OR (TI analyses OR AB analyses))) OR (TI cohort\* OR AB cohort\*) OR ((TI prospective OR AB prospective) N7 ((TI study OR AB study) OR (TI studies OR AB studies) OR (TI design OR AB design) OR (TI analysis OR AB analysis) OR (TI analyses OR AB analyses))) OR (((TI "follow up" OR AB "follow up") OR (TI followup OR AB followup)) N7 ((TI study OR AB study) OR (TI studies OR AB studies) OR (TI design OR AB design) OR (TI analysis OR AB analysis) OR (TI analyses OR AB analyses))) OR (((TI longitudinal OR AB longitudinal) OR (TI longterm OR AB longterm) OR ((TI long OR AB long) W1 (TI term OR AB term))) N7 ((TI study OR AB study) OR (TI studies OR AB studies) OR (TI design OR AB design) OR (TI analysis OR AB analysis) OR (TI analyses OR AB analyses) OR (TI data OR AB data))) OR ((TI retrospective OR AB retrospective) N7 ((TI study OR AB study) OR (TI studies OR AB studies) OR (TI design OR AB design) OR (TI analysis OR AB analysis) OR (TI analyses OR AB analyses) OR (TI data OR AB data) OR (TI review OR AB review))) OR (((TI case OR AB case) W1 (TI control OR AB control)) OR ((TI case OR AB case) W1 (TI comparison OR AB comparison)) OR ((TI case OR AB case) W1 (TI controlled OR AB controlled))) OR ((TI case-referent OR AB case-referent) N3 ((TI study OR AB study) OR (TI studies OR AB studies) OR (TI design OR AB design) OR (TI analysis OR AB analysis) OR (TI analyses OR AB analyses))) OR ((TI population OR AB population) N3 ((TI study OR AB study) OR (TI studies OR AB studies) OR (TI analysis OR AB analysis) OR (TI analyses OR AB analyses))) OR ((TI descriptive OR AB descriptive) N3 ((TI study OR AB study) OR (TI studies OR AB studies) OR (TI design OR AB design) OR (TI analysis OR AB analysis) OR (TI analyses OR AB analyses))) OR (((TI multidimensional OR AB multidimensional) OR (TI multi OR AB multi) W1 (TI dimensional OR AB dimensional))) N3 ((TI study OR AB study) OR (TI studies OR AB studies) OR (TI design OR AB design) OR (TI analysis OR AB analysis) OR (TI analyses OR AB analyses)))
- S53 MH Critical Path or MH Practice Guidelines or PT (practice guidelines or standards or protocol or critical path or care plan) or TI ("position statement\*" or "policy statement\*" or "practice parameter\*" or "best practice\*") OR AB ("position statement\*" or "policy statement\*" or "practice parameter\*" or "best practice\*") or TI (standards or guideline or guidelines) or AB (practice N1 guideline\* or treatment\* N1 guideline\*) or TI (CPG or CPGs) or TI consensus\* or AB consensus\* or AU (guideline\* or standards or consensus\* or recommendat\*) or CA (guideline\* or standards or consensus\* or recommendat\*) or TI (critical N2 path or critical N2 paths or critical N2 pathway or critical N2 pathways or critical N2 protocol\* or clinical N2 path or clinical N2 paths or clinical N2 pathway or clinical N2 pathways or clinical N2 protocol\* or practice N2 path or practice N2 paths or practice N2 pathway or practice N2 pathways or practice N2 protocol\*) or AB (critical N2 path or critical N2 paths or critical N2 pathway or critical N2 pathways or critical N2 protocol\* or clinical N2 path or clinical N2 paths or clinical N2 pathway or clinical N2 pathways or clinical N2 protocol\* or practice N2 path or practice N2 paths or practice N2 pathway or practice N2 pathways or practice N2 protocol\*) or TI recommendat\* or TI (care N2 path or care N2 paths or care N2 pathway or care N2 pathways or care N2 map or care N2 maps or care N2 plan or care N2 plans or care N2 standard\*) or AB (care N2 path or care N2 paths or care N2 pathway or care N2 pathways or care N2 map or care N2 maps or care N2 plan or care N2 plans or care N2 standard\*) or TI (algorithm\* AND (screening or examination or test or tested or testing or assessment\* or diagnosis or diagnoses or diagnosed or diagnosing)) or AB (algorithm\* AND (screening or examination or test or tested or testing or assessment\* or diagnosis or diagnoses

or diagnosed or diagnosing)) or (PT algorithm\* AND TI (screening or examination or test or tested or testing or assessment\* or diagnosis or diagnoses or diagnosed or diagnosing)) or (PT algorithm\* AND AB (screening or examination or test or tested or testing or assessment\* or diagnosis or diagnoses or diagnosed or diagnosing)) or TI (algorithm\* AND (pharmacotherap\* or chemotherap\* or chemotreatment\* or therap\* or treatment\* or intervention\*)) OR AB (algorithm\* AND (pharmacotherap\* or chemotherap\* or chemotreatment\* or therap\* or treatment\* or intervention\*)) or (PT algorithm AND TI (pharmacotherap\* or chemotherap\* or chemotreatment\* or therap\* or treatment\* or intervention\*)) or (PT algorithm AND AB (pharmacotherap\* or chemotherap\* or chemotreatment\* or therap\* or treatment\* or intervention\*))

S52 MH "meta analysis" OR MH "systematic review" OR MH "Technology, Medical/EV" OR PT "systematic review" OR PT "meta analysis" OR (((TI systematic\* OR AB systematic\*) N3 ((TI review\* OR AB review\*) OR (TI overview\* OR AB overview\*))) OR ((TI methodologic\* OR AB methodologic\*) N3 ((TI review\* OR AB review\*) OR (TI overview\* OR AB overview\*))) OR (((TI quantitative OR AB quantitative) N3 ((TI review\* OR AB review\*) OR (TI overview\* OR AB overview\*) OR (TI synthes\* OR AB synthes\*))) OR ((TI research OR AB research) N3 ((TI integrati\* OR AB integrati\*) OR (TI overview\* OR AB overview\*))) OR (((TI integrative OR AB integrative) N3 ((TI review\* OR AB review\*) OR (TI overview\* OR AB overview\*))) OR ((TI collaborative OR AB collaborative) N3 ((TI review\* OR AB review\*) OR (TI overview\* OR AB overview\*))) OR ((TI pool\* OR AB pool\*) N3 (TI analy\* OR AB analy\*)) OR ((TI "data synthes\*" OR AB "data synthes\*") OR (TI "data extraction\*" OR AB "data extraction\*") OR (TI "data abstraction\*" OR AB "data abstraction\*")) OR ((TI handsearch\* OR AB handsearch\*) OR (TI "hand search\*" OR AB "hand search\*")) OR ((TI "mantel haenszel" OR AB "mantel haenszel") OR (TI peto OR AB peto) OR (TI "der simonian" OR AB "der simonian") OR (TI dersimonian OR AB dersimonian) OR (TI "fixed effect\*" OR AB "fixed effect\*") OR (TI "latin square\*" OR AB "latin square\*")) OR ((TI "met analy\*" OR AB "met analy\*") OR (TI metanaly\* OR AB metanaly\*) OR (TI "technology assessment\*" OR AB "technology assessment\*") OR (TI HTA OR AB HTA) OR (TI HTAs OR AB HTAs) OR (TI "technology overview\*" OR AB "technology overview\*") OR (TI "technology appraisal\*" OR AB "technology appraisal\*")) OR ((TI "meta regression\*" OR AB "meta regression\*") OR (TI metaregression\* OR AB metaregression\*)) OR (MW meta-analy\* OR MW metaanaly\* OR MW "systematic review\*" OR MW "biomedical technology assessment\*" OR MW "bio-medical technology assessment\*") OR ((TI medline OR AB medline OR MW medline) OR (TI cochrane OR AB cochrane OR MW cochrane) OR (TI pubmed OR AB pubmed OR MW pubmed) OR (TI medlars OR AB medlars OR MW medlars) OR (TI embase OR AB embase OR MW embase) OR (TI cinahl OR AB cinahl OR MW cinahl)) OR (SO Cochrane OR SO health technology assessment OR SO evidence report) OR ((TI comparative OR AB comparative) N3 ((TI efficacy OR AB efficacy) OR (TI effectiveness OR AB effectiveness))) OR ((TI "outcomes research" OR AB "outcomes research") OR (TI "relative effectiveness" OR AB "relative effectiveness")) OR (((TI indirect OR AB indirect) OR (TI "indirect treatment" OR AB "indirect treatment") OR (TI mixed-treatment OR AB mixed-treatment) OR (TI bayesian OR AB bayesian)) N3 (TI comparison\* OR AB comparison\*)) OR ((TI multi\* OR AB multi\*) N3 (TI treatment OR AB treatment) N3 (TI comparison\* OR AB comparison\*)) OR ((TI mixed OR AB mixed) N3 (TI treatment OR AB treatment) N3 ((TI meta-analy\* OR AB meta-analy\*) OR (TI metaanaly\* OR AB metaanaly\*))) OR (TI "umbrella review\*" OR AB "umbrella review\*") OR ((TI multi\* OR AB multi\*) N2 (TI paramet\* OR AB paramet\*) N2 (TI evidence OR AB evidence) N2 (TI synthesis OR AB synthesis)) OR ((TI multiparamet\* OR AB multiparamet\*) N2 (TI evidence OR AB evidence) N2 (TI synthesis OR AB synthesis)) OR ((TI multi-paramet\* OR AB multi-paramet\*) N2 (TI evidence OR AB evidence) N2 (TI synthesis OR AB synthesis))

S51 S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50

S50 adolonta or Anpec or Ardinex or Asimadoline or Alvimopam or amadol or biodalgic or biokanol or Codinovo or contramal or Demerol or Dicodid or Dihydrocodeinone or dihydromorphinone or dihydrohydroxycodone or dihydrone or dilaudid or dinarkon or dolsin or dolosal or dolin or dolantin or dolargan or dolcontral or duramorph or duromorph or duragesic or durogesic or eucodal or Fedotzine or Fentanest or Fentora or Fortral or Hycodan

- or Hycon or Hydrocodone or Hydrocodeinonebitartrate or hydromorphon or hydroxycodone or isocodeine or isonipecain or jutadol or laudacon or l dromoran or levodroman or levorphan or levo-dromoran or levodromoran or lexir or lidol or lydol or morfin or morfine or morphia or morphin or morphinium or morphinene or morphium or ms contin or n-methylmorphine or n methylmorphine or nobligan or numorphan or oramorph or oxycodone or oxiconum or oxycone or oxycontin or palladone or pancodine or pethidine or phentanyl or prontosfort or robidone or skenan or sublimaze or sulfentanyl or sulfentanil or sufenta or takadol or talwin or theocodin or tramadol or tramadolhameln or tramadolor or tramadura or tramagetic or tramagit or tramake or tramal or tramex or tramundin or trasedal or theradol or tiral or topalgic or tradol or tradolpuren or tradonal or tralgiol or tramadorsch or tramadin or tramadoc or ultram or zamudol or zumalgic or zydol or zytram
- S49 alfentanil or alphaprodine or beta-casomorphin\$ or buprenorphine or carfentanil or codeine or deltorphin or dextromethorphan or dezocine or dihydrocodeine or dihydromorphine or enkephalin\$ or ethylketocyclazocine or ethylmorphine or etorphine or fentanyl or heroin or hydrocodone or hydromorphone or ketobemidone or levorphanol or lofentanil or meperidine or meptazinol or methadone or methadyl acetate or morphine or nalbuphine or opium or oxycodone or oxymorphone or pentazocine or phenazocine or phenoperidine or pirinitramide or promedol or propoxyphene or remifentanil or sufentanil or tilidine or tapentadol
- S48 "narcotic\*"
- S47 (MH "Narcotics+")
- S46 "opiate\*"
- S45 "opioid\*"
- S44 (MH "Analgesics, Opioid+")
- S43 S26 OR S42
- S42 S40 NOT S41
- S41 acute or emergency or preoperative or postoperative
- S40 S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39
- S39 ((back or discogen\* or bone or musculoskelet\* or muscle\* or skelet\* or spinal or spine or vertebra\* or joint\* or arthritis or Intestin\* or neuropath\* or neck or cervical\* or head or facial\* or complex or radicular or cervicobrachii\* or orofacial or somatic or shoulder\* or knee\* or hip or hips) N3 pain)
- S38 backache\* or backpain\* or dorsalgia\* or arthralgia\* or polyarthralgia\* or arthrodynia\* or myalgia\* or fibromyalgia\* or myodynin\* or neuralgia\* or ischialgia\* or crps or rachialgia\*
- S37 (MH "Peripheral Nervous System+/DE")
- S36 (MH "Cumulative Trauma Disorders+")
- S35 (MH "Whiplash Injuries") OR "whiplash"
- S34 ((TMJ or TMJD) and pain\*)
- S33 (MH "Temporomandibular Joint Syndrome")
- S32 "headache\*"
- S31 (MH "Headache")
- S30 (MH "Arthralgia+")
- S29 "musculoskeletal pain"
- S28 (MH "Radiculopathy") OR "radiculopathy"
- S27 (MH "Back Pain+")

S26 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16  
OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25

S25 ((noncancer\* or non-cancer\*or chronic\* or recurrent or persist\* or non-malign\*) N3 pain)

S24 (MH "Hyperalgesia")

S23 (MH "Phantom Limb") OR (MH "Phantom Pain")

S22 "intractable pain"

S21 "causalgia"

S20 (MH "Complex Regional Pain Syndromes+")

S19 "fibromyalg\*"

S18 (MH "Fibromyalgia")

S17 "migraine"

S16 (MH "Migraine")

S15 "IBS"

S14 (irritable (bowel or colon))

S13 (MH "Irritable Bowel Syndrome")

S12 "zoster"

S11 "neuralg\*"

S10 (neuropath\* N5 (pain\* or diabet\*))

S9 (MH "Diabetic Neuropathies")

S8 (MH "Neuralgia+")

S7 (MH "Arthritis, Rheumatoid+")

S6 "degenerative arthrit\*"

S5 "osteo-arthritis"

S4 "osteoarthrit\*"

S3 (MH "Osteoarthritis+")

S2 chronic N4 pain

S1 (MH "Chronic Pain")

**Database: AMED (Allied and Complementary Medicine) < 1985 to August 2023 >**

### Search Strategy

1. pain/ or abdominal pain/ or arthralgia/ or backache/ or facial pain/ or headache/ or musculoskeletal pain/ or neck pain/ or neuralgia/ or nociceptive pain/ or pain intractable/ (18826)
2. (chronic adj3 pain).mp. [mp=abstract, heading words, title] (5538)
3. osteo-arthritis.mp. (19)
4. degenerative arthrit\*.mp. (53)
5. exp Arthritis rheumatoid/ or Arthritis, Rheumatoid.mp. (2297)
6. exp Osteoarthritis/ or osteoarthritis.mp. (4625)

7. exp Neuralgia/ or Neuralgia.mp. (474)
8. exp Diabetic neuropathies/ or Diabetic Neuropath\$.mp. (1187)
9. (IBS or irritable colon or irritable bowel).mp. [mp=abstract, heading words, title] (403)
10. exp Migraine/ or migraine.mp. (827)
11. exp Fibromyalgia/ or Fibromyalgia.mp. (2000)
12. exp complex regional pain syndromes/ or complex regional pain syndromes.mp. (75)
13. exp Pain intractable/ or Pain, Intractable.mp. (464)
14. exp Phantom limb/ or Phantom Limb.mp. (191)
15. Hyperalgesia/ or Hyperalgesia.mp. (307)
16. ((noncancer\* or non-cancer\* or chronic\* or recurrent or persist\* or non-malign\*) adj3 pain).mp. (888)
17. or/1-16 (31137)
18. exp back pain/ or exp failed back surgery syndrome/ or exp low back pain/ (5273)
19. Radiculopathy/ or radiculopathy.mp. (334)
20. musculoskeletal pain/ or headache/ (1393)
21. exp Arthralgia/ (260)
22. exp Headache/ or headache.mp. (2119)
23. exp Temporomandibular joint syndrome/ or Temporomandibular Joint Dysfunction Syndrome.mp. (76)
24. ((TMJ or TMJD) and pain\*).mp. (89)
25. exp Whiplash injuries/ or whiplash.mp. (651)
26. exp repetition strain injury/ or cumulative trauma disorder/ (335)
27. cumulative trauma disorder.mp. (28)
28. exp Peripheral nervous system disease/ or Peripheral Nervous System Diseases.mp. (4234)
29. (backache\* or backpain\* or dorsalg\* or arthralgi\* or polyarthralgi\* or arthrodyni\* or myalgi\* or fibromyalgi\* or myodyn\* or neuralgi\* or ischialgi\* or crps or rachialgi\*).ab,ti. (2759)
30. ((back or discogen\* or bone or musculoskelet\* or muscle\* or skelet\* or spinal or spine or vertebra\* or joint\* or arthritis or Intestin\* or neuropath\* or neck or cervical\* or head or facial\* or complex or radicular or cervicobrach\* or orofacial or somatic or shoulder\* or knee\* or hip or hips) adj3 pain).mp. (16120)
31. exp Pain measurement/ or Pain Measurement.mp. (2235)
32. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 (25614)
33. (acute or emergency or preoperative or postoperative).ti,ab. (17441)
34. 32 not 33 (23523)
35. 17 or 34 (40752)
36. exp analgesics opioid/ or opioid.mp. or exp Narcotics/ or exp Morphine/ (1696)
37. (opioid\* or opiate\*).mp. [mp=abstract, heading words, title] (1867)



38. (alfentanil or alphaprodine or beta-casomorphin\$ or buprenorphine or carfentanil or codeine or deltorphin or dextromethorphan or dezocine or dihydrocodeine or dihydromorphine or enkephalin\$ or ethylketocyclazocine or ethylmorphine or etorphine or fentanyl or heroin or hydrocodone or hydromorphone or ketobemidone or levorphanol or lofentanil or meperidine or meptazinol or methadone or methadyl acetate or morphine or nalbuphine or opium or oxycodone or oxymorphone or pentazocine or phenazocine or phenoperidine or pirinitramide or promedol or propoxyphene or remifentanil or sufentanil or tilidine or tapentadol).mp. [mp=abstract, heading words, title] (1286)
39. narcotic\$.mp. (380)
40. (adolonta or Anpec or Ardinex or Asimadoline or Alvimopam or amadol or biodalgic or biokanol or Codinovo or contramal or Demerol or Dicodeid or Dihydrocodeinone or dihydromorphinone or dihydrohydroxycodeinone or dihydrone or dilaudid or dinarkon or dolsin or dolosal or dolin or dolantin or dolargan or dolcontral or duramorph or duromorph or duragesic or durogesic or eucodal or Fedotzine or Fentanest or Fentora or Fortral or Hycodan or Hycon or Hydrocodone or Hydrocodeinonebitartrate or hydromorphon or hydroxycodeinon or isocodeine or isonipecaïn or jutadol or laudacon or l dromoran or levodroman or levorphan or levo-dromoran or levodromoran or lexir or lidol or lydol or morfin or morfine or morphia or morphin or morphinium or morphinene or morphium or ms contin or n-methylmorphine or n methylmorphine or nobligan or numorphan or oramorph or oxycodeinon or oxiconum or oxycone or oxycontin or palladone or pancodine or pethidine or phentanyl or prontofort or robidone or skenan or sublimaze or sulfentanyl or sulfentanil or sufenta or takadol or talwin or theocodin or tramadol or tramadolhameln or tramadol or tramadura or tramagetic or tramagit or tramake or tramal or tramex or tramundin or trasedal or theradol or tiral or topalgic or tradol or tradolpuren or tradonal or tralgiol or tramadorsch or tramadin or tramadoc or ultram or zamudol or zumalgic or zydol or zytram).mp. [mp=abstract, heading words, title] (140)
41. 36 or 37 or 38 or 39 or 40 (2786)
42. exp substance related disorders/ (1716)
43. (opioid\* adj4 disorder\*).mp. [mp=abstract, heading words, title] (50)
44. (Opioid\* adj3 Abuse).mp. [mp=abstract, heading words, title] (31)
45. (Opioid\* adj3 Dependence).mp. [mp=abstract, heading words, title] (22)
46. (opioid\* adj3 addiction).mp. [mp=abstract, heading words, title] (45)
47. Opioid-Related Disorders.mp. (26)
48. (problematic adj3 opioid).mp. [mp=abstract, heading words, title] (3)
49. exp Buprenorphine/ or buprenorphine.mp. (58)
50. exp Methadone/ or methadone.mp. (155)
51. (opioid adj5 OAT).mp. [mp=abstract, heading words, title] (2)
52. opioid agonist treatment.mp. (1)
53. opioid agonist therapy.mp. (1)
54. 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 (1909)
55. 35 and 41 and 54 (203)



## Appendix 2: Content and Methodological Experts

Note that this appendix has not been copy-edited.

**Abhimanyu Sud, MD, PhD, CCFP**

Assistant Professor, Department of Family and Community Medicine, University of Toronto  
Research Chair, Primary Care and Population Health Systems, Humber River Hospital

**Jason W. Busse, DC, PhD**

Professor, Department of Anesthesia, McMaster University  
Canada Research Chair in Prevention and Management of Chronic Pain

**Danielle Rice, PhD**

Assistant Professor, Department of Psychiatry and Behavioural Neurosciences, McMaster University

**Jaris Swidrovich, PharmD**

Assistant Professor, University of Toronto

**Umair Majid, MSc**

Institute of Health Policy, Management and Evaluation, University of Toronto

**Vahid Ashoorion, MD, PhD**

Humber River Hospital, University of Toronto

For more information on CoLab  
and its work, visit [colab.cadth.ca](https://colab.cadth.ca)



Canada's Drug and  
Health Technology Agency



This work was supported by CADTH and its Post-Market Drug Evaluation Program, through funding provided by Health Canada.

**Disclaimer:** The information in this document is made available for informational and educational purposes only and should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect to the care of a particular patient or other professional judgment in any decision-making process. You assume full responsibility for the use of the information and rely on it at your own risk.

The Canadian Agency for Drugs and Technologies in Health (CADTH) has taken care to ensure that the information in this document was accurate, complete, and up-to-date when it was published, but CADTH does not make any guarantee to that effect. Your use of this information is subject to this disclaimer and the Terms of Use at [cadth.ca](https://cadth.ca). CADTH does not endorse any information, drugs, therapies, treatments, products, processes, or services. The views and opinions of third parties published in this document do not necessarily reflect those of CADTH.

**About CADTH:** CADTH is a not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system.

**About CoLab:** CoLab is a pan-Canadian network of experts in applied research, scientific methods, and data analysis. CoLab members work with CADTH's Post-Market Drug Evaluation Program to produce credible and timely evidence on post-market drug safety and effectiveness.

This document is the joint property of CADTH and Humber River Health (PI: Dr. Abhimanyu Sud). Each party has a non-exclusive, limited, royalty free, worldwide, non-transferable, fully paid-up, and irrevocable license to use the report in support of its objects and mission and reasonable operational requirements.

Copyright © 2024 Canadian Agency for Drugs and Technologies in Health